🟢 Xencor is trading 15.85% up in pre-market after positive Phase 1 XmAb819 results

Xencor is trading at $29.17, up 15.85%, after updated Phase 1 results for XmAb819.

• At the selected dose, results showed a 45.5% confirmed response rate and an 82% six-month PFS estimate.
• Xencor announced the results October 25, ahead of an October 26 webcast, and outlined development plans, including a potential registration-enabling study.
• The October 23 close was $25.18.